Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Annovis Bio Inc ANVS

Annovis Bio, Inc. is a clinical-stage drug platform company addressing neurodegeneration such as Alzheimer’s disease (AD), Parkinson’s disease (PD) and other chronic neurodegenerative diseases. The Company is developing its lead product candidate, Buntanetap, which is designed to address AD, PD, and potentially other chronic neurodegenerative diseases. Buntanetap is a synthetically produced small molecule, orally administered, brain penetrant compound. Its product candidate ANVS405 is an intravenous drug being developed for acute indications and focused on protecting the brain after traumatic brain injury (TBI) and/or stroke. ANVS405 is the same compound as Buntanetap, given in cases of acute head and brain trauma. ANVS301 is an orally administered drug being developed to increase cognitive capability in later stages of AD and dementia. ANVS301 is observed to improve memory and learning in very old rats by lowering the number of errors from six to three.


NYSE:ANVS - Post by User

Comment by Iseneschalon May 21, 2021 6:09pm
118 Views
Post# 33252660

RE:ANVS......You've all been had ....again!!!!

RE:ANVS......You've all been had ....again!!!!
Iseneschal wrote:

Annovis Bio, Inc. Announces Proposed Public Offering of Common Stock

2021-05-21 14:16 PT - News Release

Berwyn, Pennsylvania--(Newsfile Corp. - May 21, 2021) - Annovis Bio, Inc. (NYSE American: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing Alzheimer's disease (AD), Parkinson's disease (PD) and other neurodegenerative diseases, today announced that it intends to offer to sell shares of its common stock in an underwritten public offering. All of the shares of common stock are to be sold by the Company.

I see this every f'ing day.....and you ask me why I seldom hold stocks overnight.

GLTA

 



This was planned out a few months ago....check it out. Here is the link to EDGAR....

EDGAR Entity Landing Page (sec.gov)


T
his chit is done every day....you better do some research before you trade.

 Cheers !
<< Previous
Bullboard Posts
Next >>